| 卢姣云,张清媛.CDK4/6抑制剂在抗肿瘤免疫中的研究进展[J].肿瘤学杂志,2019,25(12):1080-1084. |
| CDK4/6抑制剂在抗肿瘤免疫中的研究进展 |
| Advances in Anti-tumor Immunity of CDK4/6 Inhibitors |
| 投稿时间：2018-08-09 |
| DOI：10.11735/j.issn.1671-170X.2019.12.B011 |
|
 |
| 中文关键词: CDK4 CDK6 免疫 PD-L1 |
| 英文关键词:CDK4 CDK6 Immunity PD-L1 |
| 基金项目: |
|
| 摘要点击次数: 1547 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘 要：细胞周期蛋白D（cyclin D）-细胞周期蛋白依赖性激酶4和6（CDK4/6）-神经母细胞瘤蛋白（Rb）途径在正常乳腺上皮细胞和乳腺癌细胞的增殖中起关键作用。选择性CDK4/6抑制剂（CDK4/6i）阻止Rb蛋白磷酸化，引起癌细胞在G1周期停滞。最新研究显示，CDK4/6i还可促进抗肿瘤免疫，增强免疫检查点阻断剂治疗癌症的作用，这为CDK4/6 i联合免疫疗法的新型治疗方案提供理论依据。全文重点介绍CDK4/6 i在免疫方面的影响。 |
| 英文摘要: |
| Abstract：The cyclin D-cyclin-dependent kinases 4 and 6(CDK4/6)-retinoblastoma(Rb) protein pathway plays a key role in the proliferation of both normal breast epithelium and breast cancer cells. Selective CDK4/6 inhibitors prevent phosphorylation of the Rb protein，invoking cancer cell cycle arrest in G1. Recent studies have demonstrated that CDK4/6 inhibitors can also promote anti-tumor immunity and augment the cancer-killing potential of checkpoint blockers，which provides a rationale for new combination regimen of CDK4/6 inhibitors with immunotherapy for cancer treatment. The immunological effects of CDK4/6 inhibitors are reviewed in this article. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |